Global Health Limited, operating under the Medanta brand, reported a strong financial performance for Q4 and FY25, while declaring its first-ever dividend of 25% (INR 0.50 per share). The company posted a consolidated total income of INR 9,542 million for Q4 FY25, reflecting a 14.1% year-on-year increase, and an EBITDA of INR 2,476 million, up 20% with a margin of 26.0%.
Despite a one-time exceptional expense of INR 499 million due to the merger of MHPL with GHL, adjusted Q4 PAT stood at INR 1,387 million, up 8.9% y-o-y. For the full year FY25, Medanta reported a total income of INR 37,714 million, up 12.6%, and adjusted PAT of INR 5,186 million, reflecting an 8.5% growth.
Matured hospitals contributed INR 26,118 million in revenue with 8% EBITDA growth, while developing hospitals saw a 10% revenue growth. Occupied bed days increased 10% y-o-y, and international patient revenue rose by 7.8% to INR 2,086 million. CEO Pankaj Sahni highlighted upcoming expansions including a 550-bed Noida facility (Q2 FY26) and greenfield projects in Mumbai, Pitampura, and Guwahati. Medanta also achieved several clinical milestones including its first CAR-T therapy and complex surgical innovations.